Structure Therapeutics American Stock Performance
| GPCR Stock | 18.95 0.99 4.96% |
The entity has a beta of 2.0, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Structure Therapeutics will likely underperform. At this point, Structure Therapeutics has a negative expected return of -0.45%. Please make sure to validate Structure Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Structure Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Structure Therapeutics American has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (0.30) | Five Day Return (7.94) | Year To Date Return (29.27) | Ten Year Return (23.31) | All Time Return (23.31) |
1 | Deep Track Capital, LP Increases Stake in Structure Therapeutics Inc - GuruFocus.com | 01/14/2025 |
2 | Structure Therapeutics Inc Announces Participation in Upcoming Healthcare Conferences | 01/30/2025 |
3 | Disposition of tradable shares by Fmr Llc of Structure Therapeutics subject to Rule 16b-3 | 02/06/2025 |
4 | Acquisition by Farid Ramy of 275000 shares of Structure Therapeutics subject to Rule 16b-3 | 02/07/2025 |
5 | Whats Moving Structure Therapeutics Stock Today | 02/14/2025 |
6 | Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist | 02/18/2025 |
7 | Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent ... | 02/27/2025 |
8 | Decoding Structure Therapeutics Inc A Strategic SWOT Insight | 02/28/2025 |
9 | Novo Nordisk Shares Drop After CagriSema Trial Data Falls Short of Expectations | 03/11/2025 |
10 | Structure Therapeutics Hits New 52-Week Low Time to Sell | 03/13/2025 |
11 | Acquisition by Raymond Stevens of 826890 shares of Structure Therapeutics at 7.02 subject to Rule 16b-3 | 03/14/2025 |
12 | TrueMark Investments LLC Decreases Stock Holdings in Structure Therapeutics Inc. | 03/26/2025 |
| Begin Period Cash Flow | 129.8 M |
Structure |
Structure Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,663 in Structure Therapeutics American on December 28, 2024 and sell it today you would lose (768.50) from holding Structure Therapeutics American or give up 28.86% of portfolio value over 90 days. Structure Therapeutics American is currently does not generate positive expected returns and assumes 4.6804% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Structure, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Structure Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Structure Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Structure Therapeutics American, and traders can use it to determine the average amount a Structure Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0957
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GPCR |
Estimated Market Risk
| 4.68 actual daily | 41 59% of assets are more volatile |
Expected Return
| -0.45 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Structure Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Structure Therapeutics by adding Structure Therapeutics to a well-diversified portfolio.
Structure Therapeutics Fundamentals Growth
Structure Stock prices reflect investors' perceptions of the future prospects and financial health of Structure Therapeutics, and Structure Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Structure Stock performance.
| Return On Equity | -0.19 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | 267.2 M | ||||
| Shares Outstanding | 57.34 M | ||||
| Price To Book | 1.33 X | ||||
| EBITDA | (158.23 M) | ||||
| Net Income | (122.53 M) | ||||
| Total Debt | 3.86 M | ||||
| Book Value Per Share | 15.10 X | ||||
| Cash Flow From Operations | (116.64 M) | ||||
| Earnings Per Share | (2.33) X | ||||
| Market Capitalization | 1.15 B | ||||
| Total Asset | 903.33 M | ||||
| Retained Earnings | (329.1 M) | ||||
| Working Capital | 855.19 M | ||||
About Structure Therapeutics Performance
Assessing Structure Therapeutics' fundamental ratios provides investors with valuable insights into Structure Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Structure Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.14) | (0.14) | |
| Return On Capital Employed | (0.18) | (0.19) | |
| Return On Assets | (0.14) | (0.14) | |
| Return On Equity | (0.14) | (0.13) |
Things to note about Structure Therapeutics performance evaluation
Checking the ongoing alerts about Structure Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Structure Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Structure Therapeutics generated a negative expected return over the last 90 days | |
| Structure Therapeutics has high historical volatility and very poor performance | |
| Structure Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (122.53 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Structure Therapeutics generates negative cash flow from operations | |
| Structure Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: TrueMark Investments LLC Decreases Stock Holdings in Structure Therapeutics Inc. |
- Analyzing Structure Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Structure Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Structure Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Structure Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Structure Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Structure Therapeutics' stock. These opinions can provide insight into Structure Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.